Jazz Pharmaceuticals (J7Z) Stock Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

J7Z Analyst Ratings

Strong Buy

14 Buy

1 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Jazz

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

J7Z Stock 12 Month Forecast

Average Price Target

€179.52

▲(25.14% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is €179.52 with a high forecast of €209.55 and a low forecast of €146.77. The average price target represents a 25.14% change from the last price of €143.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"91":"€91","210":"€210","120.75":"€120.8","150.5":"€150.5","180.25":"€180.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":209.54738506,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€209.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.515087768,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€179.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":146.76800654,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€146.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[91,120.75,150.5,180.25,210],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147.6,152.36518346615384,157.13036693230768,161.89555039846152,166.6607338646154,171.42591733076924,176.19110079692308,180.95628426307692,185.72146772923077,190.48665119538464,195.25183466153845,200.01701812769232,204.78220159384617,{"y":209.54738506,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147.6,150.0550067513846,152.51001350276923,154.96502025415384,157.42002700553846,159.87503375692307,162.3300405083077,164.7850472596923,167.24005401107692,169.69506076246154,172.15006751384615,174.60507426523077,177.06008101661538,{"y":179.515087768,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,147.6,147.5360005030769,147.47200100615385,147.40800150923076,147.3440020123077,147.2800025153846,147.21600301846152,147.15200352153846,147.08800402461537,147.02400452769228,146.96000503076922,146.89600553384614,146.83200603692308,{"y":146.76800654,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":115.05,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€209.55

Average Price Target€179.52

Lowest Price Target€146.77

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

€125.2→€186.53

Buy

30.03%

Upside

Reiterated

12/10/25

Jazz Pharmaceuticals price target raised to $219 from $147 at Piper SandlerJazz Pharmaceuticals price target raised to $219 from $147 at Piper Sandler

Ashwani Verma

UBS

€160.13

Hold

11.62%

Upside

Downgraded

11/24/25

Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges

Joon Lee

Truist Financial

€174.6→€187.38

Buy

30.62%

Upside

Reiterated

11/19/25

Strong Buy Rating for Jazz Pharmaceuticals Driven by Promising Ziihera Drug and Positive Market Outlook

Mohit Bansal

Wells Fargo

€144.79→€200.16

Buy

39.53%

Upside

Reiterated

11/18/25

Jazz Pharmaceuticals price target raised to $235 from $170 at Wells FargoJazz Pharmaceuticals price target raised to $235 from $170 at Wells Fargo

Brian Skorney

Robert W. Baird

€136.28→€178.01

Buy

24.09%

Upside

Reiterated

11/18/25

Jazz Pharmaceuticals price target raised to $209 from $160 at BairdJazz Pharmaceuticals price target raised to $209 from $160 at Baird

Ami Fadia

Needham

€178.86

Buy

24.69%

Upside

Reiterated

11/17/25

Promising HERIZON-GEA Trial Results Drive Buy Rating for Jazz Pharmaceuticals' ZiiheraWe expect JAZZ to trade up meaningfully today following announcement of very positive results (LINK) from the HERIZON-GEA trial, as these results are even better than the upside scenario we highlighted in our preview note (LINK). Ziihera + chemotherapy delivered a statistically significant PFS benefit and a strong positive trend in OS versus the control arm, supporting an sNDA submission in 1H26. The Ziihera + tislelizumab + chemotherapy arm showed statistically significant improvements in both PFS and OS, in PD-L1–positive as well as PD-L1-negative subgroups, results that, in our view, strongly position Ziihera- based regimens to become the new standard of care in first-line HER2+ locally advanced unresectable or metastatic GEA. The next interim OS analysis for the Ziihera + chemo arm is expected in mid-2026.

Jason Gerberry

Bank of America Securities

€195.9→€210.38

Buy

46.66%

Upside

Reiterated

11/17/25

Jazz Pharmaceuticals' Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective

Leonid Timashev

RBC Capital

€132.02→€165.24

Buy

15.19%

Upside

Reiterated

11/17/25

Jazz Pharmaceuticals price target raised to $194 from $155 at RBC CapitalJazz Pharmaceuticals price target raised to $194 from $155 at RBC Capital

Sean Laaman

Morgan Stanley

€157.57→€174.6

Buy

21.72%

Upside

Reiterated

11/17/25

Promising Phase 3 Trial Results and Expanding Indications Drive Buy Rating for Jazz Pharmaceuticals

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€191.64

Buy

33.59%

Upside

Reiterated

11/17/25

Jefferies Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Annabel Samimy

Stifel Nicolaus

€195.9

Buy

36.56%

Upside

Reiterated

11/06/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Cytokinetics (NASDAQ: CYTK) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Joseph Thome

TD Cowen

€174.6

Buy

21.72%

Upside

Reiterated

11/06/25

Jazz Pharmaceuticals: Strong Financial Performance and Promising Prospects Reinforce Buy Rating

Jessica Fye

J.P. Morgan

€173.75→€169.49

Buy

18.16%

Upside

Reiterated

10/27/25

Jazz Pharmaceuticals price target lowered to $199 from $204 at JPMorganJazz Pharmaceuticals price target lowered to $199 from $204 at JPMorgan

Marc Goodman

Leerink Partners

€187.38→€183.12

Buy

27.66%

Upside

Reiterated

10/07/25

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Leerink Partners

David Hoang

Deutsche Bank

€144.79→€147.35

Buy

2.72%

Upside

Reiterated

10/03/25

Deutsche Bank Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)Deutsche Bank analyst David Hoang raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $173.00 (from $170.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

€125.2→€186.53

Buy

30.03%

Upside

Reiterated

12/10/25

Jazz Pharmaceuticals price target raised to $219 from $147 at Piper SandlerJazz Pharmaceuticals price target raised to $219 from $147 at Piper Sandler

Ashwani Verma

UBS

€160.13

Hold

11.62%

Upside

Downgraded

11/24/25

Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges

Joon Lee

Truist Financial

€174.6→€187.38

Buy

30.62%

Upside

Reiterated

11/19/25

Strong Buy Rating for Jazz Pharmaceuticals Driven by Promising Ziihera Drug and Positive Market Outlook

Mohit Bansal

Wells Fargo

€144.79→€200.16

Buy

39.53%

Upside

Reiterated

11/18/25

Jazz Pharmaceuticals price target raised to $235 from $170 at Wells FargoJazz Pharmaceuticals price target raised to $235 from $170 at Wells Fargo

Brian Skorney

Robert W. Baird

€136.28→€178.01

Buy

24.09%

Upside

Reiterated

11/18/25

Jazz Pharmaceuticals price target raised to $209 from $160 at BairdJazz Pharmaceuticals price target raised to $209 from $160 at Baird

Ami Fadia

Needham

€178.86

Buy

24.69%

Upside

Reiterated

11/17/25

Jason Gerberry

Bank of America Securities

€195.9→€210.38

Buy

46.66%

Upside

Reiterated

11/17/25

Jazz Pharmaceuticals' Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective

Leonid Timashev

RBC Capital

€132.02→€165.24

Buy

15.19%

Upside

Reiterated

11/17/25

Jazz Pharmaceuticals price target raised to $194 from $155 at RBC CapitalJazz Pharmaceuticals price target raised to $194 from $155 at RBC Capital

Sean Laaman

Morgan Stanley

€157.57→€174.6

Buy

21.72%

Upside

Reiterated

11/17/25

Promising Phase 3 Trial Results and Expanding Indications Drive Buy Rating for Jazz Pharmaceuticals

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€191.64

Buy

33.59%

Upside

Reiterated

11/17/25

Jefferies Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Annabel Samimy

Stifel Nicolaus

€195.9

Buy

36.56%

Upside

Reiterated

11/06/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Cytokinetics (NASDAQ: CYTK) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Joseph Thome

TD Cowen

€174.6

Buy

21.72%

Upside

Reiterated

11/06/25

Jazz Pharmaceuticals: Strong Financial Performance and Promising Prospects Reinforce Buy Rating

Jessica Fye

J.P. Morgan

€173.75→€169.49

Buy

18.16%

Upside

Reiterated

10/27/25

Jazz Pharmaceuticals price target lowered to $199 from $204 at JPMorganJazz Pharmaceuticals price target lowered to $199 from $204 at JPMorgan

Marc Goodman

Leerink Partners

€187.38→€183.12

Buy

27.66%

Upside

Reiterated

10/07/25

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Leerink Partners

David Hoang

Deutsche Bank

€144.79→€147.35

Buy

2.72%

Upside

Reiterated

10/03/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

1 Month

xxx

Success Rate

27/43 ratings generated profit

Average Return

+1.40%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.79% of your transactions generating a profit, with an average return of +1.40% per trade.

3 Months

xxx

Success Rate

21/33 ratings generated profit

Average Return

+2.55%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +2.55% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

16/19 ratings generated profit

Average Return

+18.28%

reiterated a buy rating last month

Copying Joon Lee's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +18.28% per trade.

2 Years

xxx

Success Rate

17/19 ratings generated profit

Average Return

+30.82%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +30.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

J7Z Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, J7Z has received 29 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. J7Z average Analyst price target in the past 3 months is 179.52.

Each month's total comprises the sum of three months' worth of ratings.

J7Z Financial Forecast

J7Z Earnings Forecast

Next quarter’s earnings estimate for J7Z is €5.45 with a range of €4.96 to €5.75. The previous quarter’s EPS was €6.93. J7Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.

J7Z Sales Forecast

Next quarter’s sales forecast for J7Z is €984.52M with a range of €950.75M to €1.04B. The previous quarter’s sales results were €960.25M. J7Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.

J7Z Stock Forecast FAQ

What is DE:J7Z’s average 12-month price target, according to analysts?

Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 179.52.

What is DE:J7Z’s upside potential, based on the analysts’ average price target?

Jazz Pharmaceuticals has 25.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Jazz Pharmaceuticals a Buy, Sell or Hold?

Jazz Pharmaceuticals has a consensus rating of Strong Buy, which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.

What is Jazz Pharmaceuticals’s share price target?

The average share price target for Jazz Pharmaceuticals is 179.52. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €209.55 ,and the lowest forecast is €146.77. The average share price target represents 25.14% Increase from the current price of €143.45.

What do analysts say about Jazz Pharmaceuticals?

Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Jazz Pharmaceuticals?

To buy shares of DE:J7Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Jazz Pharmaceuticals (J7Z) Stock Forecast & Price Target

J7Z Analyst Ratings

J7Z Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jazz Pharmaceuticals

J7Z Analyst Recommendation Trends

J7Z Financial Forecast

J7Z Earnings Forecast

J7Z Sales Forecast

J7Z Stock Forecast FAQ

Detailed List of Analyst Forecasts